AC Immune says Parkinson's drug slows progression

AC Immune posts positive data for Parkinson’s immunotherapy

Shares of AC Immune rose by double-digits on news that the company, encouraged by new data, now intends to ask drug regulators for feedback to “potentially accelerate” the time to an approval filing.

AC Immune says Parkinson's drug slows progression

AC Immune's active immunotherapy study backs up the alpha-synuclein hypothesis in Parkinson's disease, after disappointments in earlier trials.

AC Immune reports positive interim data of a-syn active immunotherapy in early PD - BioTuesdays

AC Immune (NASDAQ: ACIU) has announced positive interim safety and efficacy results from the Phase 2 VacSYn trial of its wholly-owned anti-alpha-synuclein (a-syn) active immunotherapy, ACI-7104.056, in early Parkinson’s disease (PD). According to AC Immune, the results show, for the first time, that targeting a-syn pathology with an active immunotherapy could potentially slow the rate of progression of PD. Disease-related biomarker results, incl…

AC Immune says early biomarker data are promising in Parkinson's, but clinical benefit remains unclear

Swiss biotech AC Immune, researching immunological treatments for neurodegenerative disorders, reported interim Parkinson’s disease data Thursday, suggesting it may slow the progression of the condition. But the interpretation of its clinical endpoints remains unclear, particularly ...